Application of a single-objective, hybrid genetic algorithm approach to pharmacokinetic model building

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 39, Issue 4, 2012, Pages 393-414

  Sherer, Eric A ^a,b   Sale, Mark E ^a,c   Pollock, Bruce G ^d,e   Belani, Chandra P ^f   Egorin, Merrill J ^g   Ivy, Percy S ^h   Lieberman, Jeffrey A ⁱ   Manuck, Stephen B ^e   Marder, Stephen R ^j   Muldoon, Matthew F ^k   Scher, Howard I ^l   Solit, David B ^l   Bies, Robert R ^a,d  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RICHARD L ROUDEBUSH VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Next Level Solutions   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f PENN STATE CANCER INSTITUTE   (United States)

^g UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^h NATIONAL CANCER INSTITUTE   (United States)

ⁱ Columbia University College of Physicians and Surgeons ^*  (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k UNIVERSITY OF PITTSBURGH   (United States)

^l MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

more..

Author keywords

Genetic Algorithms; Model building; Pharmacokinetics

Indexed keywords

ALVESPIMYCIN; CITALOPRAM; ESCITALOPRAM; OLANZAPINE; PERPHENAZINE; RISPERIDONE; ZIPRASIDONE;

ALZHEIMER DISEASE; ANALYTICAL ERROR; ARTICLE; COVARIANCE; DATA ANALYSIS; DRUG EFFICACY; FEASIBILITY STUDY; GENETIC ALGORITHM; HUMAN; MAJOR DEPRESSION; PARAMETRIC TEST; PHARMACOKINETICS; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA; SIMULATION; STATISTICAL MODEL; SYSTEMATIC ERROR;

ADULT; ALGORITHMS; COMPUTER SIMULATION; CROSS-SECTIONAL STUDIES; GENETICS; HUMANS; MIDDLE AGED; MODELS, BIOLOGICAL; PHARMACOKINETICS;

EID: 84865526608     PISSN: 1567567X     EISSN: 15738744     Source Type: Journal    
DOI: 10.1007/s10928-012-9258-0     Document Type: Article

References (24)

1. Efroymson MA (1960) Multiple regression analysis. In: Ralston A, Wilf HS (eds) Mathematical methods for digital computers. Wiley, New York
2. Wade JR, Beal SL, Sambol NC (1994) Interaction between structural, statistical, and covariate models in population pharmacokinetic analysis. J Pharmacokinet Pharmacodyn 22:165-177 (Pubitemid 24288140)
3. Bies RR, Muldoon MF, Pollock BG, Manuck S, Smith G, Sale ME (2006) A genetic algorithm-based, hybrid machine learning approach to model selection. J Pharmacokinet Pharmacodyn 33:195-221
4. Zhu JZ (2002) Optimal reconfiguration of electrical distribution networks using the refined genetic algorithm. Elect Power Syst Res 62:37-42 (Pubitemid 34614291)
5. Moles CG, Mendes P, Banga JR (2003) Parameter estimation in biochemical pathways: a comparison of global optimization methods. Genome Res 13:2467-2474 (Pubitemid 37428271)
6. Reeves CR (1995) A genetic algorithm for flowship sequencing. Comput Oper Res 22:5-13
7. Schmidt M, Lipson H (2009) Distilling free-form natural laws from experimental data. Science 324:81-85
8. Goldberg DE (1989) Genetic algorithms in search, optimization, and machine learning. Addison-Wesley, Boston
9. Sale M, Pollock BG, Bies RR (2011) Identification of pareto nondominated sets of NONMEM models using a multi-objective evolutionary algorithm. American Conference on Pharmcometrics http://www.go-acop.org/sites/default/files/webform/ Mark/Sale/1.doc. Accessed 20 Dec 2011
10. Jonsson ET, Karlsson MO (1998) Automated covariate model building within NONMEM. Pharm Res 15:1463-1468 (Pubitemid 28427937)
11. Ribbing J, Nyberg J, Caster O, Johnsson EN (2007) The lasso: a novel method for predictive covariate model building in nonlinear mixed effects models. J Pharmacokinet Pharmacodyn 34:485-517 (Pubitemid 47038127)
12. Mosteller RD (1987) Simplified calculation of body surface area. N Engl J Med 317:1098
13. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41
14. Bigos KL, Pollock BG, Coley KC, Miller DD, Marder SR, Aravagiri M, Kirshner MA, Schneider LS, Bies RR (2008) Sex, race, and smoking impact olanzapine exposure. J Clin Pharmacol 48:157-165
15. Jin Y, Pollock BG, Coley K, Miller D, Marder SR, Florian J, Schneider L, Lieberman J, Kirshner M, Bies RR (2010) Population pharmacokinetics of perphenazine in schizophrenia patients from CATIE: impact of race and smoking. J Clin Pharmacol 50:73-80
16. Feng Y, Pollock BG, Coley K, Marder S, Miller D, Kirshner M, Aravagiri M, Schneider L, Bies RR (2008) Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study. Br J Clin Pharmacol 65:629-639
17. Wessels AM, Bies RR, Pollock BG, Schneider LS, Lieberman JA, Stroup S, Li CH, Coley K, Kirshner MM, Marder SR (2011) Population pharmacokinetic modeling of ziprasidone in patients from the CATIE Study. J Clin Pharmacol 51(11):1587-1591
18. Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM, McGee MF, Simpson GM, Stevens MC, Lieberman JA (2003) The National Institute of Mental Health clinical antipsychotic trials of intervention effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull 29:15-31 (Pubitemid 36871054)
19. Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsaio JK, Ismail MS, Lebowitz BD, Lyketsos CG, Ryan JM, Stroup TS, Sultzer DL, Weintraub D, Leiberman JA (2006) CATIE-AD Study Group. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 355:1525-1538 (Pubitemid 44547805)
20. Frank E, Cassano GB, Rucci P, Fagiolini A, Maggi L, Kraemer HC, Kupfer DJ, Pollock B, Bies R, Mingaonkar V, Pilkonis P, Shear MK, Thompson WK, Grochocinshi VJ, Scocco P, Buttenfield J, Forgione RN (2008) Addressing the challenges of a cross-national investigation: lessons from the Pittsburgh-Pisa study of treatment-relevant phenotypes of unipolar depression. Clin Trials 5:253-261
21. Jin Y, Pollock BG, Frank E, Cassano GB, Rucci P, Muller DJ, Kennedy JL, Forgione RN, Kirshner M, Kepple G, Fagiolini A, Kupfer DJ, Bies RR (2010) Effect of age, weight, and CYP2C19 genotype on escitalopram exposure. J Clin Pharmacol 50:62-72
22. Muldoon MF, Mackey RH, Korytkowski MT, Flory JD, Pollock BG, Manuck SB (2006) The metabolic syndrome is associated with reduced central serotonergic responsivity in healthy volunteers. J Clin Endocrinol Metab 91:718-721 (Pubitemid 43236948)
23. Jonsson EN, Karlsson MO (1999) Xpose: an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 20:511-528
24. Fleiss JL (1981) Statistical methods for rates and proportions, 2nd edn. Wiley, New York